TY - JOUR
T1 - Study protocol of "Worth the Walk"
T2 - A randomized controlled trial of a stroke risk reduction walking intervention among racial/ethnic minority older adults with hypertension in community senior centers
AU - Kwon, Ivy
AU - Choi, Sarah
AU - Mittman, Brian
AU - Bharmal, Nazleen
AU - Liu, Honghu
AU - Vickrey, Barbara
AU - Song, Sarah
AU - Araiza, Daniel
AU - McCreath, Heather
AU - Seeman, Teresa
AU - Oh, Sang Mi
AU - Trejo, Laura
AU - Sarkisian, Catherine
N1 - Funding Information:
This work was supported by the National Institute of Neurological Disorders and Stroke [1U54NS081764] and the National Institute on Aging [1K24AG047899-01]. Additional sources of support for this project include the National Institute on Aging UCLA Older Americans Independence Center [P30AG028748] and National Institute on Aging Resource Centers for Minority Aging Research IV/Center for Health Improvement of Minority Elderly III ([2] P30AG021684).
Funding Information:
The Worth the Walk intervention is culturally-tailored and based in social cognitive theory [21, 22] and attribution theory [23, 24]. It incorporates elements such as verbal persuasion, goal setting, problem solving, and attribution retraining techniques that encourage participants to modify their expectations for aging (i.e., teach older adults not to attribute mutable stroke risk factors to aging) and change their own behavior to reduce stroke risk. In a previous National Institute on Aging-funded RCT of a behavioral intervention to increase walking—¡Caminemos! (R01 AG024460-05) [25, 26]—our team enrolled 572 older Latinos from 27 community senior centers and randomized them to receive either an attribution retraining intervention teaching not to attribute sedentary lifestyle to old age, or an active control group (series of lectures). We followed participants for 24 months; the intervention successfully increased walking levels (mean increase 6207 steps/day) more than the control group (p = 0.04). Though this efficacy study succeeded in meaningfully increasing walking levels, the intervention delivery was supported by National Institutes of Health (NIH) funding of research staff, limiting the intervention’s sustainability. With the current effectiveness trial, we have adopted many components of the Caminemos intervention, linking them with stroke and stroke risk factor education to create a new culturally-tailored intervention, and have integrated the new intervention directly into senior center programming without relying on NIH-funded staff for implementation (essentially making the efficacy-to-effectiveness transition). Our study builds on the expertise our team acquired in conducting the Caminemos trial, including recruitment, retention, screening and enrollment protocols, pedometer training, and group leader training (see below).
Publisher Copyright:
© Kwon et al.
PY - 2015/6/15
Y1 - 2015/6/15
N2 - Background: Stroke disproportionately kills and disables ethnic minority seniors. Up to 30 % of ischemic strokes in the U.S. can be attributed to physical inactivity, yet most Americans, especially older racial/ethnic minorities, fail to participate in regular physical activity. We are conducting a randomized controlled trial (RCT) to test a culturally-tailored community-based walking intervention designed to reduce stroke risk by increasing physical activity among African American, Latino, Chinese, and Korean seniors with hypertension. We hypothesize that the intervention will yield meaningful changes in seniors' walking levels and stroke risk with feasibility to sustain and scale up across the aging services network. Methods/Design: In this randomized single-blind wait-list control study, high-risk ethnic minority seniors are enrolled at senior centers, complete baseline data collection, and are randomly assigned to receive the intervention "Worth the Walk" immediately (N = 120, intervention group) or in 90 days upon completion of follow-up data collection (N = 120, control group). Trained case managers employed by the senior centers implement hour-long intervention sessions twice weekly for four consecutive weeks to the intervention group. Research staff blinded to participants' group assignment collect outcome data from both intervention and wait-list control participants 1 and 3-months after baseline data collection. Primary outcome measures are mean steps/day over 7 days, stroke knowledge, and self-efficacy for reducing stroke risk. Secondary and exploratory outcome measures include selected biological markers of health, healthcare seeking, and health-related quality of life. Outcomes will be compared between the two groups using standard analytic methods for randomized trials. We will conduct a formal process evaluation to assess barriers and facilitators to successful integration of Worth the Walk into the aging services network and to calculate estimated costs to sustain and scale up the intervention. Data collection is scheduled to be completed in December 2016. Discussion: If this RCT demonstrates superior improvements in physical activity and stroke knowledge in the intervention group compared to the control group and is found to be sustainable and scalable, Worth the Walk could serve as a primary stroke prevention model for racial/ethnic communities across the nation. Trial registration: ClinicalTrials.gov NCT02181062; registered on June 30, 2014.
AB - Background: Stroke disproportionately kills and disables ethnic minority seniors. Up to 30 % of ischemic strokes in the U.S. can be attributed to physical inactivity, yet most Americans, especially older racial/ethnic minorities, fail to participate in regular physical activity. We are conducting a randomized controlled trial (RCT) to test a culturally-tailored community-based walking intervention designed to reduce stroke risk by increasing physical activity among African American, Latino, Chinese, and Korean seniors with hypertension. We hypothesize that the intervention will yield meaningful changes in seniors' walking levels and stroke risk with feasibility to sustain and scale up across the aging services network. Methods/Design: In this randomized single-blind wait-list control study, high-risk ethnic minority seniors are enrolled at senior centers, complete baseline data collection, and are randomly assigned to receive the intervention "Worth the Walk" immediately (N = 120, intervention group) or in 90 days upon completion of follow-up data collection (N = 120, control group). Trained case managers employed by the senior centers implement hour-long intervention sessions twice weekly for four consecutive weeks to the intervention group. Research staff blinded to participants' group assignment collect outcome data from both intervention and wait-list control participants 1 and 3-months after baseline data collection. Primary outcome measures are mean steps/day over 7 days, stroke knowledge, and self-efficacy for reducing stroke risk. Secondary and exploratory outcome measures include selected biological markers of health, healthcare seeking, and health-related quality of life. Outcomes will be compared between the two groups using standard analytic methods for randomized trials. We will conduct a formal process evaluation to assess barriers and facilitators to successful integration of Worth the Walk into the aging services network and to calculate estimated costs to sustain and scale up the intervention. Data collection is scheduled to be completed in December 2016. Discussion: If this RCT demonstrates superior improvements in physical activity and stroke knowledge in the intervention group compared to the control group and is found to be sustainable and scalable, Worth the Walk could serve as a primary stroke prevention model for racial/ethnic communities across the nation. Trial registration: ClinicalTrials.gov NCT02181062; registered on June 30, 2014.
KW - Behavioral intervention
KW - Clinical trial
KW - Ethnic minority
KW - Primary prevention
KW - Seniors
KW - Stroke
UR - http://www.scopus.com/inward/record.url?scp=84931270385&partnerID=8YFLogxK
U2 - 10.1186/s12883-015-0346-9
DO - 10.1186/s12883-015-0346-9
M3 - Article
C2 - 26072359
AN - SCOPUS:84931270385
SN - 1471-2377
VL - 15
JO - BMC Neurology
JF - BMC Neurology
IS - 1
M1 - 91
ER -